Revolution Medicines, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Revolution Medicines, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q2 2024.
  • Revolution Medicines, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 12.6 %, a 23.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 12.6 -3.9 -23.7% Jun 30, 2024
Q1 2024 13.3 -5.37 -28.8% Mar 31, 2024
Q4 2023 14.2 -8.01 -36% Dec 31, 2023
Q3 2023 15.8 -7.6 -32.5% Sep 30, 2023
Q2 2023 16.5 -5.27 -24.2% Jun 30, 2023
Q1 2023 18.7 +0.39 +2.13% Mar 31, 2023
Q4 2022 22.2 +6.73 +43.4% Dec 31, 2022
Q3 2022 23.4 +8.8 +60.3% Sep 30, 2022
Q2 2022 21.7 +6.62 +43.8% Jun 30, 2022
Q1 2022 18.3 +0.58 +3.28% Mar 31, 2022
Q4 2021 15.5 -4.51 -22.5% Dec 31, 2021
Q3 2021 14.6 -14.6 -50% Sep 30, 2021
Q2 2021 15.1 Jun 30, 2021
Q1 2021 17.7 Mar 31, 2021
Q4 2020 20 Dec 31, 2020
Q3 2020 29.2 Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.